Marianne Davies on Immunotherapy-Related Side Effects in Lung Cancer

Marianne Davies, from Smilow Cancer Hospital, Yale School of Nursing, provides an overview of immunotherapy-related side effects that patient with lung cancer may experience.

Related Videos

Related Content

Advertisement

June 11th 2025

FDA Approves Ibtrozi for ROS1+ Advanced Non-Small Cell Lung Cancer

Spencer Feldman

The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

June 10th 2025

The LAURA Trial May Lead to a New Era of Care in Lung Cancer

Ryan Scott

Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.

February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

June 8th 2025

Targeted Chemo Improves Survival in Early-Stage Lung Cancer

Jordyn Sava

Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.

June 6th 2025

MVdeltaC Earns Orphan Drug Status for Pleural Mesothelioma

Spencer Feldman

The FDA granted orphan drug designation to MVdeltaC, a measles virus-based immunotherapy, for pleural mesothelioma, supporting its future development.

Related Content

Advertisement

June 11th 2025

FDA Approves Ibtrozi for ROS1+ Advanced Non-Small Cell Lung Cancer

Spencer Feldman

The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

June 10th 2025

The LAURA Trial May Lead to a New Era of Care in Lung Cancer

Ryan Scott

Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.

February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

June 8th 2025

Targeted Chemo Improves Survival in Early-Stage Lung Cancer

Jordyn Sava

Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.

June 6th 2025

MVdeltaC Earns Orphan Drug Status for Pleural Mesothelioma

Spencer Feldman

The FDA granted orphan drug designation to MVdeltaC, a measles virus-based immunotherapy, for pleural mesothelioma, supporting its future development.